source
- Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding roundIsomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…
- Evaxion Biotech Shifts R&D Focus Exclusively to Cancer Vaccines, Halts Infectious and Autoimmune ProgramsEvaxion Biotech announced it is ending its infectious disease and autoimmune research programs to concentrate solely on oncology. The company’s most advanced candidate is EVX-01, a therapeutic can…